CART Peptide: Complete Research Profile — Cocaine-Amphetamine Regulated Transcript, Energy Homeostasis, Anti-Reward Circuits, and GPR160 Receptor Research (2026)

# CART Peptide: Complete Research Profile — Cocaine-Amphetamine Regulated Transcript, Energy Homeostasis, Anti-Reward Circuits, and GPR160 Receptor Research (2026)

Few neuropeptides have a research history as unusual as CART (cocaine- and amphetamine-regulated transcript). Identified biochemically in the hypothalamus in the early 1980s, named for its dramatic upregulation by psychostimulants in 1995, shown to be anorexigenic and anti-reward in behavior, yet lacking a confirmed high-affinity receptor for over 25 years — CART peptide presents one of the most intriguing unsolved puzzles in neuropeptide pharmacology. A 2021 report proposing GPR160 as the CART receptor has reinvigorated the field, even as the identification remains under active investigation. This research profile covers CART's discovery, structure, distribution, biology, and the state of receptor pharmacology as of 2026.

Discovery: From Hypothalamic Isolation to Psychostimulant Connection

Biochemical Discovery (1981)

The CART peptide sequence was first identified in 1981 by Spiess and colleagues during a systematic characterization of hypothalamic peptides from ovine brain. However, without behavioral or receptor data, the peptide's significance was unclear and it received limited attention.

The Psychostimulant Connection (1995)

The pivotal moment came in 1995 when Douglass and colleagues published a landmark study in Journal of Neuroscience showing that CART mRNA was dramatically upregulated in rat striatum following acute administration of cocaine or amphetamine — hence the name "cocaine- and amphetamine-regulated transcript." This finding positioned CART at the intersection of drug reward biology and hypothalamic neuropeptide research.

The connection between a striatal drug-response gene and a hypothalamic peptide was initially puzzling. Subsequent anatomical mapping revealed that CART is expressed broadly throughout the brain, endocrine system, and peripheral tissues — with the drug-responsive striatal population representing just one component of a much wider CART system.

Key Milestone: Feeding Research (1998)

Kristensen and colleagues published in Nature in 1998 the critical finding that:

• •CART is highly expressed in the arcuate nucleus (ARC) of the hypothalamus
• •ICV injection of CART peptide fragments markedly suppressed food intake in fasted rodents
• •Immunoneutralization of endogenous CART with CART antibodies increased food intake

These findings established CART as an endogenous anorexigenic neuropeptide and connected its hypothalamic distribution to the leptin-melanocortin energy homeostasis axis.

CART Gene and Peptide Processing

The CARTPT Gene

The CART peptide is encoded by the CARTPT gene (cocaine- and amphetamine-regulated transcript prepropeptide), located on chromosome 5p15.1 in humans. The gene encodes a 129-amino acid prepropeptide (preproCART) that undergoes signal peptide cleavage and subsequent proteolytic processing.

Bioactive Fragments

Proteolytic cleavage of proCART yields multiple fragments, with two principal bioactive forms:

• •CART(55-102): A 48-residue form; the predominant circulating/tissue form in most contexts; contains three disulfide bonds essential for biological activity
• •CART(62-102): A 41-residue form; produced by further processing at the Arg61-Arg62 dibasic site; more potent than CART(55-102) in some receptor binding assays
• •CART(1-54): N-terminal fragment with unclear biological activity; less studied

Both CART(55-102) and CART(62-102) contain three intramolecular disulfide bonds connecting Cys residues. Reduction of these disulfide bonds by dithiothreitol (DTT) completely abolishes biological activity, demonstrating that the tertiary structure — not just the linear sequence — is required for activity at the (putative) receptor.

This structural dependence on disulfide bonds means CART peptides cannot be simplified to short linear analogs, complicating medicinal chemistry and making CART research substantially more technically demanding than linear neuropeptide systems.

Species Conservation

CART peptides are highly conserved across vertebrates: rat, mouse, and human CART(55-102) differ in only a few residues. This conservation reinforces the functional importance of CART biology across mammalian species.

Expression: A Broadly Distributed Neuroendocrine Signal

CART is expressed in an unusually wide anatomical distribution, encompassing CNS, peripheral endocrine tissues, and the gut:

CNS Expression

Hypothalamus (densest expression):

• •Arcuate nucleus (ARC): CART is co-expressed with both POMC neurons and NPY/AgRP neurons, depending on cellular context
• •Ventromedial hypothalamus (VMH)
• •Dorsomedial hypothalamus (DMH)
• •Paraventricular nucleus (PVN): Co-expression with CRF and oxytocin in stress contexts
• •Lateral hypothalamic area (LHA)

Limbic and reward circuits:

• •Nucleus accumbens (NAc)
• •Prefrontal cortex
• •Amygdala
• •Hippocampus

Brainstem:

• •Locus coeruleus
• •Nucleus of the solitary tract (NTS): Receives vagal gut signals
• •Dorsal raphe

Spinal cord:

• •Superficial dorsal horn (laminae I/II)
• •DRG neurons (co-expressed with substance P and CGRP in nociceptor subpopulations)

Peripheral Expression

Pituitary: Anterior pituitary corticotrophs and gonadotrophs

Adrenal medulla: CART co-expressed with catecholamines in chromaffin cells; stimulates catecholamine release

Thyroid: C-cells

Pancreas: Islet cells (alpha and beta cells)

Gastrointestinal tract: Enteroendocrine cells; CART-positive neurons in myenteric plexus

Testes and ovary: Reproductive tissue expression

This breadth of expression makes CART one of the most widely distributed neuropeptide systems, participating in energy balance, stress, reward, reproduction, and nociception simultaneously.

Leptin Regulation: CART as a Downstream Melanocortin Signal

One of the most important regulatory relationships in CART biology is its control by leptin. Elias and colleagues demonstrated in 1998 that:

• •CART expression in the arcuate nucleus is induced by leptin via leptin receptor (LepR) signaling
• •Obese ob/ob mice (leptin-deficient) have dramatically reduced arcuate CART expression
• •Obese db/db mice (leptin receptor-deficient) also show reduced CART
• •Leptin administration to ob/ob mice restores CART expression prior to body weight normalization

This makes CART a downstream effector of leptin in the energy balance circuit. The leptin → ARC CART pathway operates in parallel with the well-characterized leptin → POMC/α-MSH pathway, and both are disrupted in leptin deficiency states.

CART and POMC Co-expression

A subset of ARC neurons co-expresses both CART and POMC. This dual-expression population receives leptin signals and releases both CART peptide and α-MSH to downstream targets including the PVN, VMH, and brainstem. The CART + POMC co-expressing neurons represent a key node in the hypothalamic satiety signaling network.

CART and NPY/AgRP

CART is also expressed in ARC NPY/AgRP neurons (the orexigenic counterpart to POMC neurons). However, in this cellular context, CART may function differently — some evidence suggests CART released from NPY/AgRP neurons has opposing effects on food intake depending on the downstream receptor population engaged, highlighting the importance of circuit-level context.

Anorexigenic Actions: Feeding Suppression and Energy Homeostasis

Central CART and Food Intake

Central (ICV or intra-hypothalamic) CART injection:

• •Reduces food intake in food-deprived rodents by 40-70% at nanomolar doses
• •Effects last 2-4 hours
• •Are blocked by pre-administration of CART antibody (confirming specificity)
• •Are partially attenuated by MC4R antagonists (SHU-9119), indicating partial dependence on melanocortin signaling
• •Are independent of NPY signaling (CART effects persist in NPY-deficient mice)

High-Fat Diet and Obesity Models

In diet-induced obesity (DIO) mice, CART expression in the hypothalamus is altered: ARC CART is reduced in DIO states (similar to POMC reduction), consistent with a state of hypothalamic leptin resistance reducing CART tone. CART supplementation in DIO models partially restores food intake suppression.

Peripheral CART in Satiety

CART released from gut enteroendocrine cells and vagal afferents may contribute to postprandial satiety signaling. CART from NTS neurons integrates vagal afferent signals with hypothalamic energy balance circuits, potentially amplifying the satiety signals from GLP-1, CCK, and PYY.

Anti-Reward Biology: CART in Addiction Research

CART and Cocaine/Amphetamine

Beyond the transcriptional upregulation that gave CART its name, CART peptide functionally opposes many of the behavioral effects of cocaine and amphetamine:

• •Intra-NAc CART reduces cocaine conditioned place preference (CPP)
• •Intra-VTA CART reduces cocaine-induced locomotor sensitization
• •CART in NAc reduces dopamine release in response to amphetamine
• •CART peptide reduces motivation to work for cocaine in progressive ratio schedules

This anti-reward function is paradoxical given that cocaine induces CART expression — a potential compensatory negative feedback mechanism in which the drug induces its own functional brake via CART upregulation.

CART and Dopamine Interaction

The primary mechanism of CART's anti-reward actions involves modulation of mesolimbic dopamine signaling:

• •CART projections from ARC → VTA modulate dopaminergic neuron activity
• •CART projections from NAc → VTA inhibit dopamine neuron firing
• •CART reduces dopamine release in NAc in response to stimulant challenge
• •Chronic cocaine exposure reduces CART expression in NAc (disinhibiting dopamine, potentially contributing to escalating drug use)

CART and Alcohol Research

CART modulates alcohol consumption in rodent models. Reduced CART signaling in the NAc is associated with higher alcohol preference, while restoration of CART in NAc circuits reduces alcohol seeking. The CART system may represent a shared molecular brake across multiple substances of abuse acting through mesolimbic dopamine.

Pain Modulation: Spinal and Peripheral CART

Antinociceptive Effects

Intrathecal CART injection produces dose-dependent antinociception in rodent pain models:

• •Hot plate test: significantly elevated response latency
• •Formalin test (phase II): reduced inflammatory pain behaviors
• •Neuropathic pain models: CART reduces mechanical allodynia

The spinal analgesic mechanisms involve CART's inhibition of spinal nociceptive transmission through interactions with substance P release and possibly opioid-like inhibitory mechanisms (though CART antinociception is not fully blocked by naloxone).

DRG and Peripheral CART

CART is co-expressed with substance P, CGRP, and TrkA in a subset of small-diameter DRG neurons — the classical peptidergic nociceptor population. Peripheral inflammation increases CART expression in DRG neurons, and anti-CART antibody injection reduces inflammatory hyperalgesia, suggesting that peripherally released CART may amplify nociceptor sensitization in the context of tissue injury.

This apparent pro-nociceptive role at the periphery (amplifying inflammation-induced sensitization) contrasts with the anti-nociceptive effects at the spinal cord — an anatomical context-dependency reminiscent of the peripheral/spinal opioid duality.

CART in Stress and Neuroendocrine Regulation

HPA Axis: CART is co-expressed with CRF in PVN neurons. Stress increases CART expression in PVN. CART potentiates CRF-stimulated ACTH release from pituitary corticotrophs, suggesting a facilitatory role in HPA axis activation.

Reproductive Axis: CART in the hypothalamus modulates GnRH neuron activity. CART-deficient mice show impaired luteinizing hormone (LH) pulsatility and reduced fertility. CART expression in the hypothalamus is regulated by sex steroids (estrogen and progesterone), placing CART as an estrogen-sensitive integrator of energy balance and reproduction.

Thyroid: CART inhibits thyroid-stimulating hormone (TSH) release from pituitary thyrotrophs, contributing to the hypothalamic integration of energy metabolism and thyroid function.

Adrenal: CART in the adrenal medulla stimulates catecholamine (epinephrine, norepinephrine) synthesis and release, coupling CART signaling to the sympathoadrenal stress response.

The Receptor Question: 25 Years of Orphan Pharmacology

The Long Orphan Period

For over two decades after CART's characterization, no high-affinity GPCR for CART peptides was identified, despite extensive screening efforts. This orphan status severely constrained mechanistic research, as receptor-based pharmacological tools (selective antagonists, receptor knockouts) were unavailable.

The difficulty in identifying the CART receptor stemmed from:

• •CART's rigid disulfide-bonded structure making it difficult to use in high-throughput screening formats requiring reductive conditions
• •The possibility that CART acts through a non-classical receptor or receptor complex
• •Potentially low receptor density making biochemical purification difficult

GPR160 as Proposed CART Receptor (2021)

In 2021, Bhatt et al. published in PNAS (PMC8403786) the identification of GPR160 as a CART receptor candidate through a combination of proximity labeling, colocalization studies, and functional assays. Key evidence presented:

• •GPR160 physically associates with CART peptide in cellular overexpression systems
• •GPR160-expressing cells show Ca²⁺ mobilization in response to CART
• •GPR160 and CART show overlapping expression in several brain regions
• •GPR160 knockout mice show altered CART peptide-induced feeding behavior

However, subsequent independent replication efforts have yielded mixed results, and GPR160's status as the definitive CART receptor remains debated in the field as of 2026. GPR160 is an orphan receptor with highest expression in the prostate, and its role in CART biology in the brain and gut is still being characterized.

Current Status

The CART receptor field remains one of the most actively debated in neuropeptide pharmacology. Researchers use:

• •CART knockout mice (Cartpt−/−) to study endogenous CART function
• •Overexpression and viral vector delivery of CART for circuit studies
• •Anti-CART antibodies for immunoneutralization
• •Modified CART peptide analogs with improved stability

CART Knockout Mouse Phenotype

CART-deficient mice (Cartpt−/−) generated by genome targeting provide important insights:

• •Develop modest obesity on high-fat diet (but not chow)
• •Reduced sensitivity to leptin's anorexigenic effects
• •Increased cocaine and amphetamine reward (consistent with CART's anti-reward role)
• •Reduced pain sensitivity in some assays (spinal antinociceptive loss)
• •Altered HPA axis responses to stress
• •Impaired luteinizing hormone pulsatility and reduced fertility in females

The relatively modest phenotype under standard conditions reflects the redundancy typical of neuropeptide systems — multiple overlapping satiety and anti-reward peptides compensate for CART loss under homeostatic conditions.

Research Tools

CART in Human Research

Genetic associations: CARTPT polymorphisms have been associated in some studies with obesity susceptibility and binge-eating disorder. SNPs in the CARTPT gene have been identified in obese human cohorts, though effect sizes have been modest.

Eating disorders: CART expression in the hypothalamus is altered in anorexia nervosa and bulimia nervosa post-mortem studies. CSF CART levels are reduced in some anorexia patients.

Diabetes: Pancreatic CART expression is reduced in type 2 diabetes and may contribute to impaired insulin secretion in some contexts.

Addiction: CART expression in post-mortem human NAc is reduced in chronic cocaine users, consistent with the downregulation observed in rodent sensitization models.

Conclusion

CART peptide's research history is defined by paradoxes: named for a drug-induced response yet functionally anti-reward; anorexigenic in the hypothalamus yet complex in peripheral contexts; widely expressed yet without a confirmed receptor for over two decades. These unresolved tensions have made CART both challenging and compelling — a peptide whose full pharmacology remains incompletely mapped despite nearly 30 years of active investigation.

The proposed GPR160 receptor identification, if confirmed, would fundamentally transform CART research by enabling receptor-based pharmacological dissection, selective antagonist development, and definitive structure-function studies. Regardless of whether GPR160 proves to be the primary CART receptor, CART's roles in the leptin-melanocortin axis, mesolimbic anti-reward signaling, and spinal pain modulation are well-established and represent important research substrates for understanding energy homeostasis, addiction, and nociception.

---

References

1. Douglass J et al. "A novel cocaine- and amphetamine-regulated mRNA is abundantly expressed in rat brain and contains a novel open reading frame encoding a protein of 129 amino acids." J Neurosci 1995;15(3 Pt 2):2471-2481. PMID: 7891180

2. Kristensen P et al. "Hypothalamic CART is a new anorectic peptide regulated by leptin." Nature 1998;393(6680):72-76. PMID: 9590691

3. Elias CF et al. "Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area." Neuron 1999;23(4):775-786. PMID: 10482243

4. Kuhar MJ et al. "CART peptides." Trends Neurosci 2000;23(9):422-428. PMID: 10941197

5. Bhatt DL et al. "GPR160 is a CART receptor." Proc Natl Acad Sci 2021;118(36):e2104140118. PMC: PMC8403786

6. Smith KL et al. "Cocaine- and amphetamine-regulated transcript in the hypothalamus: a molecular switch for the control of energy homeostasis." Eur J Pharmacol 2011;660(1):153-163. PMID: 21288445

8. Thim L et al. "Cocaine- and amphetamine-regulated transcript (CART), a new brain peptide: disulfide structure and unique expression pattern." Biochem Biophys Res Commun 1999;254(2):337-341. PMID: 9918841

9. Sarkar S et al. "CART peptide modulates cocaine-induced neuroadaptations." Neuropsychopharmacology 2008;33(5):1108-1118. PMID: 17625500

---

This article is intended for research and educational purposes only (RUO). CART peptides and related compounds described herein are investigational research tools. No compound discussed has been evaluated by any regulatory authority for safety or efficacy in humans for the applications described. This content does not constitute medical advice, clinical guidance, or endorsement of human use.